Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study

Andrea Dennis, PhD1; Daniel J Cuthbertson, PhD2; Dan Wootton, PhD3; Michael Crooks, MD4,5; Mark Gabbay, MD6; Nicole Eichert, PhD1; Sofia Mouchti1; Michele Pansini, MD7; Adriana Roca-Fernandez1; Helena Thomaides-Brears, PhD1; Matt Kelly, PhD1; Matthew Robson, PhD1; Lyth Hishmeh8; Emily Attree, MD9; Melissa Heightman, PhD10; Rajarshi Banerjee, PhD1; Amitava Banerjee, DPhil10,11,12,\*

1Perspectum, Oxford, UK

2Institute of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK

3Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK

4Department of Respiratory Medicine, Hull and East Yorkshire Hospitals NHS Foundation Trust, Hull, UK

5Institute of Clinical and Applied Health Research, University of Hull, Hull, UK

6Institute of Population Health Sciences, University of Liverpool, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK

7Department of Radiology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford

8Long COVID SOS, Oxford, UK

9UKDoctors#Longcovid, London, UK

10Department of Medicine, University College London Hospitals NHS Foundation Trust, London, UK

11Institute of Health Informatics, University College London, London, UK

12Department of Cardiology, Barts Health NHS Trust, London, UK

\***Corresponding Author:**

Professor Amitava Banerjee MA MPH DPhil FHEA FAHA FESC FRCP FRCP (Ed) FFCI

Professor of Clinical Data Science and Honorary Consultant Cardiologist

Institute of Health Informatics, University College London

Adjunct Professor in Public Health

Amrita Institute of Medical Sciences, Kochi, India

E-mail: ami.banerjee@ucl.ac.uk

Tel: 02035495449

**Manuscript word count:** 2990 words

**Key points:**

* Question: What is the prevalence of organ impairment in long COVID at 6- and 12-months post-COVID-19?
* Findings: In a prospective study of 536 mainly non-hospitalised individuals, all were symptomatic at 6 months and 59% had single organ impairment. Although symptom burden decreased, organ impairment persisted in the 331 followed-up at 12 months post-COVID-19.
* Meaning: Organ impairment in long COVID has implications for symptoms, quality of life and longer-term health, signalling need for prevention and integrated care of long COVID.

Abstract

**Background:** Standardised assessment across multiple organs over time is lacking in long COVID, particularly in non-hospitalised individuals. We set out to determine the prevalence of organ impairment in long COVID patients at 6 and at 12 months after initial symptoms and to explore links to clinical presentation.

**Methods:** In individuals recovered from acute COVID-19, we assessed symptoms, health status, and multi-organ tissue characterisation and function in two non-acute settings (Oxford and London). Physiological and biochemical investigations were performed at baseline on all individuals and those with organ impairment were reassessed. Primary outcome was prevalence of single and multi-organ impairment at 6 and 12 months post-COVID-19.

**Results:** 536 individuals (mean 45 years, 73% female, 89% white, 32% healthcare workers, 13% acute COVID-19 hospitalisation) completed baseline assessment (median: 6 months post-COVID-19). 331 (62%) with organ impairment or incidental findings had follow up, with reduced symptom burden from baseline (median number of symptoms 10 and 3, at 6 and 12 months). Extreme breathlessness (38% and 30%), cognitive dysfunction (48% and 38%) and poor health-related quality of life (EQ-5D-5L<0.7; 57% and 45%) were common at 6 and 12 months, and associated with female gender, younger age and single organ impairment. Single and multi-organ impairment were present in 69% and 23% at baseline, persisting in 59% and 27% at follow-up.

**Conclusion:** Organ impairment persisted in 59% of 331 followed up at 1 year post-COVID-19, with implications for symptoms, quality of life and longer-term health, signalling need for prevention and integrated care of long COVID.

**Trial Registration**: ClinicalTrials.gov Identifier: NCT04369807

**Keywords:** COVID-19, long COVID, organ impairment, quality of life, prevention, integrated care

# **Background**

Symptoms of long COVID, also known as post-acute sequelae of COVID-19 (PASC), are well-documented1,2, but natural history is poorly characterised, whether by symptoms, organ impairment or function3–5. Among 3,762 individuals with suspected or confirmed COVID-19 debilitating symptoms lasted beyond 35 weeks with fatigue, breathlessness and cognitive dysfunction being the most frequent6. In the UK’s largest long COVID clinic, non-hospitalised patients required specialist referral at similar rates to hospitalised patients and were more likely to report breathlessness and fatigue, with reduced health-related quality of life (HRQoL)7. A US study in 270,000 individuals post-COVID-19 showed one-third had persistent symptoms at 3-6 months (more common than post-influenza symptoms based on a matched cohort with otherwise similar risk factors), possibly due to direct organ-specific rather than general viral effects, and potentially informing development of effective treatments8.

Long COVID may be linked to severity of initial illness in some hospitalised patients, but prognostic factors are neither defined nor investigated systematically in non-hospitalised patients7–9. To conduct trials of possible therapies for long COVID, we need stratification by symptoms or investigations3. Our interim MRI data in 201 individuals showed mild organ impairment in the heart, lungs, kidneys, liver, pancreas, and spleen, with single and multi-organ impairment in 70% and 29%, respectively, 4 months after COVID-199. Clinical utility of these MR metrics for chronic and multi-system conditions has been shown10-11. More severe ongoing symptoms of breathlessness and fatigue were associated with myocarditis (p<0.05)9, but symptoms and multi-organ manifestations have not been correlated.

In the UK and other countries, health system and research responses have begun at scale12. However, clinical patient pathways are unclear and there are still no proven, evidence-based therapies, whether in subgroups or in the overall long COVID population. Single and multi-organ impairment need investigation over medium- and long-term to assess resource utilisation and health system needs.

In individuals with long COVID, we therefore prospectively investigated:

Symptoms, organ impairment and function over 1 year, particularly relating to ongoing breathlessness, cognitive dysfunction and HRQoL

Associations between symptoms and organ impairment

# **Methods**

# Patient Population and Study Design

This study took place during the COVID-19 emergency, before formal definition of long COVID. Patients with evidence of COVID-19 who were no longer suffering from active SARS-CoV-2 infection but had ongoing symptoms could enter the study. Retrospective evaluation of the duration of the symptoms defined individuals who had long COVID based on continuing symptoms for ³ 12 weeks, as informed by the earliest WHO, NICE and NHS England guidance regarding post-COVID complications that are now in current guidelines, policy and practice in the UK7.

Recruitment was by response to advertisement or specialist referral to two non-acute imaging sites (Perspectum, Oxford and Mayo Clinic Healthcare, London) from April 2020 to August 2021 (the period of COVID-19 waves 1 and 2 in UK) and written informed consent. (Supplementary Methods for inclusion and exclusion criteria). Those with evidence of organ impairment, based on bloods, MRI, or incidental findings (organ abnormalities such as lesions, cysts, abnormal vessels and tumours incidentally detected during the MRI analysis), were invited for 6-month follow-up (contacted on ≥2 occasions to minimise loss to follow-up). Each visit comprised MRI and blood investigations (full blood count, biochemistry) and online questionnaires completed beforehand9.

# Diagnostic Assessment in Non-acute Settings

Quantitative multi-organ MRI (CoverScan, Perspectum, Oxford) was used to assess organ impairment as previously reported (Figure S1)9, using healthy controls (no prior COVID-19 diagnosis, no hospital discharge ≥4 months prior to enrolment and contraindications to MRI; 59 in Oxford, 33 in London). Participants underwent a 40-minute MRI scan of lungs, heart, kidney, liver, pancreas and spleen on 1.5T or 3T Siemens scanners at three imaging sites (Oxford: MAGNETOM Aera 1.5T, Mayo Healthcare London: MAGNETOM Vida 3T, Chenies Mews Imaging Centre London: MAGNETOM Prisma 3T). MR metrics were standardised to deliver a single report interpretable by clinicians. Each report included 49 organ-specific metrics with reference ranges to determine impairment (updated from our prior study10) after determining distribution of each metric in healthy controls matched for age and sex (n=92) and for organ volumes from healthy controls representing complete sex and height subgroups (N=1835) in this study and UK Biobank13 (Table S1a and b). Repeatability of the metrics was evaluated in healthy controls using standardized performance testing criteria. Technical success was determined by reporting quality-assured measures for each variable reported herein, and overall, in delivering a report for each patient.

# Symptoms, Function and Organ Impairment

Assessment focused on commonly reported symptoms, HRQoL9 and degree of breathlessness (Dyspnoea 12 scale7). Participants were asked at follow-up about time off work due to COVID-19 (not done at baseline). Multi-organ impairment at baseline and follow-up was defined as ≥2 MRI measurements from different organs outside reference ranges. Further details are in Supplementary Methods.

# Statistical Analysis

The study was powered based on the primary outcome measure: to determine the prevalence of heart, kidney and liver injury in a cohort of patients recovering from COVID-19, using multi-parametric MRI, defined relative to pre-defined thresholds from a healthy cohort. Using a published method14, required sample size for 10% expected prevalence15, 5% allowable margin of error and 95% confidence and allowing for 10% attrition rate, was 507. Analyses were in R version 4.1.0, defining statistical significance by uncorrected p-value<0.05 (2-sided). Normally distributed-continuous variables: mean(standard deviation, SD); non-normally distributed-continuous: median(interquartile range, IQR), and categorical variables: frequency(percentage). Fisher’s exact or Mcnemar’s tests were used for unpaired and paired categorical data and paired/unpaired t-test or Wilcox tests were used for paired/unpaired continuous data, depending on the normality of the underlying distribution. Stepwise multi-variable logistic regression was performed for associations with symptom groups and a sensitivity analysis excluding metabolic syndrome performed (Supplementary Methods).

# **Results**

# Study Population for Diagnostic Assessment in Non-Acute Settings

536 individuals (mean age 45 years, 73% female, median BMI 25 kg/m2, 13% COVID-19 hospitalisation, 32% healthcare workers) were included at baseline (Figure 1). Demographics were comparable to healthy controls (Table S1a). Most were ‘UK first wave’ (COVID-19 January-September 2020: n=497); 39 ‘second wave’ (COVID-19 after September 2020). Over half of individuals (n=296, 55%) had experienced acute COVID-19 confirmed by antibody or PCR tests and they had marginally higher BMI (25 kg/m2 (22, 28)) compared to those with clinical diagnosis of COVID-19 (26 kg/m2 (23, 30); Table S2). Median time from initial COVID-19 symptoms to baseline assessment was 182 days (IQR: 132-222).

388 (72%) with organ impairment identified at baseline, from blood or MRI assessment, were eligible for follow-up, of which 331 (62% of baseline cohort) completed (the follow-up group). Median time from baseline to follow-up assessment was 196 days (IQR: 182-209). Age and BMI were higher in those who completed both visits, and more had been hospitalised for acute COVID-19, compared to those without organ impairment who were not eligible for follow-up (Table S3). In the follow-up group, demographics and risk factors showed no major differences between baseline and follow-up (Table 1). Technical success of MRI and integrated in-person assessment was 99.1% and 98.3% at baseline and follow-up assessments, respectively. Reports summarising findings were delivered to patients and primary care clinicians in all cases.

# Symptoms over 1 Year

In the whole cohort, at baseline all participants were symptomatic (Table 1, Figure 2A), including those not eligible for follow-up (Figure S2).Females and individuals with obesity were more likely to have ≥1 of systemic symptoms, cardiopulmonary symptoms or poor HRQoL (p<0.001, 0.006 and <0.001 for sex and p=0.002, 0.012 and 0.004 for BMI) (Table S4).

In the follow-up group, at baseline and follow-up, participants reported a median 10 (IQR: 8-11) symptoms and 3 (0-5) symptoms (p<0.001), respectively. At baseline, all five symptom groups had similar prevalence (systemic: 48%, cardiopulmonary: 43%, severe breathlessness: 38%, cognitive dysfunction: 48%, poor HRQoL: 57%); 12% reported none of these symptoms but other less common symptoms instead. At follow-up, symptoms were reduced, particularly systemic (1%) and cardiopulmonary (5%) (p<0.001). Exceptions were fatigue, breathlessness and cognitive dysfunction, where prevalence remained high (Figure 2B). Some participants reported these symptoms only at follow-up*.* Most common symptoms improved by follow-up: fatigue (98% to 64%), myalgia (89% to 35%), shortness of breath (90% to 47%), headache (85% to 34%), chest pain (81% to 38%), fever (73% to 2%), cough (75% to 11%) and sore throat (71% to 11%). 60/331(18%) had resolved all symptoms at follow-up (Table 2).

# Function over 1 Year

HRQoL was poor at baseline in the whole cohort of long COVID individuals: median VAS score 60% (IQR: 40-70%) and median reported health utility index score 0.67 (IQR: 0.48-0.77). The most highly ranked sub-optimal health dimensions were problems completing usual activities of living and pain (56% and 45% reporting moderate to extreme difficulties).

These difficulties were also observed at baseline in the follow-up group [(median VAS score 60% (IQR: 40-70%) and median reported health utility index score 0.67 (IQR: 0.48-0.77)] (Figures S3 and S4). At follow-up, there was increased health utility index score to 0.71 (0.56, 0.81) (p<0.001), but 42% still reported utility score <0.7 and 28% still complained of severe breathlessness. Almost every individual at follow-up (271/302, 90%) had taken COVID-19-related time off work (median: 125 days IQR: [35-296]). At follow-up, 95% of healthcare workers had taken time off work (median 180 days [41-308]) and 62 (63%) had taken >100 days off work. Those with ongoing symptoms reported taking more time off work (median 172 days [42-300]) compared to those whose symptoms had resolved (median 54 days [21-120]) (Table 2).

# Organ Impairment over 1 Year

Most standard-of-care biochemical investigations were within normal range and not predictive of outcomes (Table S5), except lactate dehydrogenase (59/306 [19%] and 70/319 [22%]), creatinine kinase (26/313 [8%] and 41/323 [13%]); cholesterol (152/313 [49%] and 157/326 [48%]); and mean cell haemoglobin concentration (62/313 [20%] and 49/324 [15%], p=0.05) which were elevated at both baseline and follow-up.

On MRI of 536 participants at baseline, 59% and 23% had impairment in ≥1 and ≥2 organs respectively (Figure 2C), although impairment was usually mild (Table S6), e.g., among participants with cardiac impairment, none had severe heart failure. Liver steatosis, kidney fibro-inflammation and splenomegaly at baseline were more frequent in all symptom groups (Table S4). Liver steatosis was associated with systemic symptoms and severe breathlessness (Figure S5).

In the follow-up group, single organ impairment between visits improved but remained high (69% at baseline and 59% at follow-up had impairment in ≥1 organ, p<0.001) without improvement in individual metrics between visits (Figure 2D). Multi-organ impairment did not improve (29% to 27%, p=0.336). Individuals without organ impairment had lower symptom burden compared to those with at least one organ impairment (Figure S6). At baseline, lung impairment (lower fractional area change) and impairment in ≥3 organs had the highest symptom burden. Healthcare workers were more likely to have liver impairment (p=0.015 at baseline and p=0.034 at follow-up) than the rest of the cohort.

In individuals without symptoms at follow-up (n=60), organ impairment was present in 43 (72%) at baseline and 37 (62%) at follow-up (Table 2, Figure S6). In symptomatic participants at follow-up (n=264), there were 84 (32%) and 112 (42%) without organ impairment at baseline and follow-up, respectively.

# Associations Between Symptoms and Organ Impairment

Looking at individual symptoms and by five symptom groups, neither abnormal biochemical investigations nor organ impairment were predictive of full symptom resolution at follow-up (Tables S4-S7). Several liver-specific parameters were associated with specific symptom burden (Figure 3, Table S7). High liver fat was present in 58/187 with severe breathlessness but only 70/328 without severe breathlessness at baseline. Conversely, low liver fat was more likely in those without severe breathlessness at both timepoints, in the follow-up group. High liver volume at follow-up was associated with lower HRQoL. Hepatomegaly was present in 20/138 with poor QoL but in only 8/167 with better QoL at follow-up.

# **Discussion**

In this UK prospective study of largely non-hospitalised long COVID, we have four new findings. First, we confirm multi-organ impairment at 6- and 12- months in 29% of individuals with long COVID, with persistent symptoms and reduced function. Second, despite some associations between organ impairment and symptoms, there is currently insufficient evidence for distinct long COVID subtypes. Blood biomarkers, the current standard of care, showed no relation to clinical presentation. Third, symptoms, blood investigations and quantitative, multi-organ MRI did not predict trajectory or recovery. Fourth, we demonstrate feasibility of scalable, multi-organ assessment in non-acute settings in the pandemic context.

Several studies confirm persistence of symptoms in individuals with long COVID up to 1 year16. We now add that 3 in 5 people with long COVID have impairment in at least one organ, and 1 in 4 have impairment in two or more organs, in some cases without symptoms. Impact on quality of life and time off work, particularly in healthcare workers, is a major concern for individuals, health systems and economies17. Many healthcare workers had no prior illness (2% diabetes, 2% heart disease and 22% asthma, which may play a pathophysiologic role18), but of 172 such participants, 19 were still symptomatic at follow-up and off work at a median of 180 days. We need comparison with similar analyses from other long COVID studies, and other long-term conditions19, with considerable workforce planning implications. There have been heterogenous methods to investigate long COVID, whether qualitative20-21 or quantitative5, or symptom surveys6 versus cohort studies4,22. Most research still focuses on individual organs23–25. The scale of long COVID burden necessitates action to develop, evaluate and implement evidence-based investigation, treatment and rehabilitation26 (e.g., STIMULATE-ICP and other studies4).

Metabolic disease, including non-alcoholic liver disease and diabetes, are postulated to play a role in pathogenesis of severe COVID-19 and possibly long COVID27. We observe associations with markers of liver dysfunction, and increased risk of symptoms in female and obese individuals with long COVID, which has been shown previously28–29. Cognitive impairment appears to develop in the natural history of long COVID in some patients. However, underlying mechanisms of the condition or syndrome remain elusive. We did not find evidence by symptoms, blood investigations or MRI to clearly define long COVID subtypes.

We observed symptom resolution at 12 months in 29% of individuals with long COVID, particularly with cardiopulmonary and systemic symptoms, aligning with other longitudinal studies5,13,19. Our findings of reductions in HRQoL and time at work reinforce prior research and are concerning, despite improvement over time. Future research must consider associations between symptoms, multi-organ impairment and function in larger cohorts, enabling clearer stratification and evaluation of treatments.

The COVERSCAN study was initiated in the early pandemic first wave when face-to-face assessment and investigation, and reduced health system capacity were major concerns for patients and health professionals. In the UK and other countries, long COVID carries high burden of investigations and healthcare utilisation across specialties, and definitive care pathways are lacking. We show feasibility, acceptability and scalability of a rapid (40-minute), multi-organ MRI protocol for practice and research. Alongside routine clinical assessment and blood tests, CoverScan can exclude organ impairment in integrated, multidisciplinary care pathways30. Such MRI assessment has potential application beyond the pandemic for multi-system assessment and investigation, including in lower resource settings.

# Implications for Research

There are three research implications. First, complex intervention trials, including care pathways from investigation to rehabilitation are needed to evaluate therapies. Second, associations between symptoms, symptom groups, blood investigations and MRI must be investigated in larger populations. Third, long COVID pathophysiology is still unclear, and should ideally be studied at the same time as clinical trials.

# Implications for Clinical Practice and Public Health

There are three practice and policy implications. First, CoverScan could be used to rule out organ impairment and to identify subgroups requiring specialist referral. Second, long COVID is a multi-organ condition, needing multi-organ assessment and multi-disciplinary care. Third, poor 1-year post-COVID recovery rates highlight need for rehabilitation and integrated care, relevant to other long-term conditions.

# **Strengths and Limitations**

To date, this is the largest, comprehensive, systematic, multi-organ, post-COVID study over 1 year. The study cohort is representative of long COVID resulting from the first and second waves in the UK in a mainly community setting in terms of risk factors and acute COVID-19 hospitalisation7,8. There are limitations. We acknowledge that the study may not be representative of the condition in patients infected with other variants of SARS-CoV-2, or of long COVID in mainly hospitalised patients. Our study recruited patients who self-referred from online patient support forums and social media rather than a systematic screen of post-COVID patients, as long COVID clinics were not yet established. We did not have history and imaging prior to the pandemic and so it is difficult to determine if COVID-19/long COVID caused impairment. Despite low prevalence of self-reported comorbidities in this cohort, in some participants the organ impairment we identified may be due to pre-existing, undiagnosed comorbidities rather than direct post-COVID sequelae. There was no assessment of brain function. Not all participants had a laboratory-confirmed COVID-19 diagnosis. Generalizability of results from the UK’s first COVID-wave to the global population requires further exploration. We successfully delivered multi-organ MRI to assess organ health, but clinical utility remains to be determined. Health utilisation (e.g. primary care interactions) and economic burden of long COVID were not assessed. Time off work was not assessed at baseline when the UK was in lockdown with a national furlough scheme in operation. Patients with normal assessment at baseline were not followed up to minimise in person contact and due to resource and funding constraints. Therefore, whilst 222/536 (41%) patients at baseline were defined as normal after assessment, we cannot say they had better outcomes, and this may represent a selection bias. Nevertheless, we can model cost-saving of a single assessment versus multiple assessments to achieve a discharge decision.

# **Conclusions**

Long COVID symptoms commonly persist at 12 months, even in those not severely affected by acute COVID-19. Diagnosis and follow up of long COVID can be performed in non-acute settings. Continued research in multi-system assessment and pharmacotherapy for those reporting ongoing fatigue, breathlessness, and cognitive problems is required to address long COVID burden, in parallel with mechanistic studies to understand pathophysiology.

# **Declarations**

# Ethical Approval

The protocol was approved by South Central - Berkshire B Research Ethics Committee (20/SC/0185) and registered (<https://clinicaltrials.gov/ct2/show/NCT04369807>).

**Consent to participate**

All participants gave full informed consent

**Consent for publication**

Not applicable.

**Availability of data and materials**

All relevant data to the study are included in the manuscript and the supplementary material.

**Competing interests**

AD, NE, SF, MP, ARF, HTB, MK, MR and RB are employees of Perspectum.

**Funding**

The study was partly financed by an Amendment to a European Commission’s Horizon 2020 grant 719445 (AMENDMENT Reference No AMD-719445-8): Non-invasive rapid assessment of chronic liver disease using Magnetic Resonance Imaging with LiverMultiScan (RADIcAL).

**Authors' contributions**

Study design: AD, RB, COVERSCAN team. Patient recruitment: RB, COVERSCAN team. Data collection: MW, COVERSCAN team. Data analysis: AD, NE, H T-B, AR-F, AB, SM COVERSCAN team. Data interpretation: AB, AD, NE, HT-B, RB. Initial manuscript drafting: AB, AD, RB. Critical review of early and final versions of the manuscript: all authors. Specialist input: MW, AB (cardiology); RB, MH, DW, MC, DJC (general medicine); MH, MC, DW (long COVID); MB, RB, MR (imaging); AD (statistics); AB (epidemiology/public health); MG (primary care); LH, EA (patient and public involvement).

# **Acknowledgements**

We are grateful to Alison Telford for statistical critique of this manuscript. AB has received funding from NIHR (including the STIMULATE-ICP study), AstraZeneca, European Union, UK Research and Innovation and British Medical Association. DW is funded by an NIHR advanced fellowship. MG is funded by ARC and DH&SC NIHR.

References

1. Groff D, Sun A, Ssentongo AE, et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Network Open. 2021;4(10). doi:10.1001/jamanetworkopen.2021.28568

2. Soriano JB, Murthy S, Marshall JC et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2021;(S1473-3099(21)00703-9.).

3. Yong SJ LS. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev Med Virol . 2021;(e2315.).

4. Routen A, O’Mahoney L, Ayoubkhani D, et al. Understanding and tracking the impact of long COVID in the United Kingdom. Nature Medicine. 2022;28(1). doi:10.1038/s41591-021-01591-4

5. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862). doi:10.1038/s41586-021-03553-9

6. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine. 2021;38. doi:10.1016/j.eclinm.2021.101019

7. Heightman M, Prashar J, Hillman TE, et al. Post-COVID-19 assessment in a specialist clinical service: A 12-month, single-centre, prospective study in 1325 individuals. BMJ Open Respiratory Research. 2021;8(1). doi:10.1136/bmjresp-2021-001041

8. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Medicine. 2021;18(9). doi:10.1371/journal.pmed.1003773

9. Dennis A, Wamil M, Alberts J, et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: A prospective, community-based study. BMJ Open. 2021;11(3). doi:10.1136/bmjopen-2020-048391

10. Borlotti A, Thomaides-Brears H, Georgiopoulos G, et al. The additive value of cardiovascular magnetic resonance in convalescent COVID-19 patients. Frontiers in Cardiovascular Medicine. 2022; 9:854750.

11. Heber SD, Hetterich H, Lorbeer R et al. Pancreatic fat content by magnetic resonance imaging in subjects with prediabetes, diabetes, and controls from a general population without cardiovascular disease. PLoS One. 2017 May 17;12(5):e0177154.

12. Augustin M, Schommers P, Stecher M, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. The Lancet Regional Health - Europe. 2021;6. doi:10.1016/j.lanepe.2021.100122

13. Wilman HR, Kelly M, Garratt S, et al. Characterisation of liver fat in the UK Biobank cohort. PLoS ONE. 2017;12(2). doi:10.1371/journal.pone.0172921

14. Naing, L., Winn, T. & Rusli, B. N. Practical issues in calculating the sample size for prevalence studies. Arch. Orofac. Sci. 1, 9–14 (2006).

15. Chen T, Wu D, Chen H et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091.

16. Han Q, ZB, DL, SA. Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms. Pathogens. 2022;11(2):269.

17. Martin C, Luteijn M, Letton W, Robertson J, McDonald S. A model framework for projecting the prevalence and impact of Long-COVID in the UK. PLoS ONE. 2021;16(12 December). doi:10.1371/journal.pone.0260843

18. Cervia C, Zurbuchen Y, Taeschler P. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun . 2022;13(1):446.

19. Gabbay M, Shiels C, Hillage J. Factors associated with the length of fit note-certified sickness episodes in the UK. Occupational and Environmental Medicine. 2015;72(7). doi:10.1136/oemed-2014-102307

20. Shah R, Ali FM, Nixon SJ, Ingram JR, Salek SM, Finlay AY. Measuring the impact of COVID-19 on the quality of life of the survivors, partners and family members: A cross-sectional international online survey. BMJ Open. 2021;11(5). doi:10.1136/bmjopen-2020-047680

21 Macpherson K Cooper K, Harbour J et al. Experiences of living with long COVID and of accessing healthcare services: a qualitative systematic review. BMJ Open. 2022;12(1):e050979.

22. Tleyjeh IM, Saddik B, Ramakrishnan RK, et al. Long term predictors of breathlessness, exercise intolerance, chronic fatigue and well-being in hospitalized patients with COVID-19: A cohort study with 4 months median follow-up. Journal of Infection and Public Health. 2022;15(1). doi:10.1016/j.jiph.2021.11.016

23. Badenoch JB, Rengasamy ER, Watson C, et al. Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. Brain Communications. 2022;4(1). doi:10.1093/braincomms/fcab297

24. Yan Z, Yang M, Lai CL. Long covid-19 syndrome: A comprehensive review of its effect on various organ systems and recommendation on rehabilitation plans. Biomedicines. 2021;9(8). doi:10.3390/biomedicines9080966

25. Xie Y, Xu E, Bowe B. Long-term cardiovascular outcomes of COVID-19. Nature. Published online February 7, 2022.

26. Murray E, GH, BJ, BA. Development, deployment and evaluation of digitally enabled, remote, supported rehabilitation for people with long COVID-19 (Living With COVID-19 Recovery): protocol for a mixed-methods study. BMJ Open. 2022;12(2):e057408.

27. Khunti K, Davies MJ, Kosiborod MN, Nauck MA. Long COVID — metabolic risk factors and novel therapeutic management. Nature Reviews Endocrinology. 2021;17(7). doi:10.1038/s41574-021-00495-0

28. Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: Retrospective cohort study. The BMJ. 2021;372. doi:10.1136/bmj.n693

29. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nature Medicine. 2021;27(4). doi:10.1038/s41591-021-01292-y

30. Parker AM, Brigham E, Connolly B, et al. Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care. The Lancet Respiratory Medicine. 2021;9(11). doi:10.1016/S2213-2600(21)00385-4

**Figures and Tables**

Figure 1: Study population from recruitment to follow-up.

Figure 2: Proportion of individuals with long COVID and symptoms (A: at baseline in whole cohort vs in follow-up group; B: at baseline vs at follow-up in follow-up group) or impairment (C in whole cohort and in follow-up group vs healthy controls; D at baseline vs at follow-up in follow-up group).

Figure 3: Association between risk factors and: (A) severe breathlessness at baseline; (B) Poor HRQoL at follow-up.

Table 1: Characteristics of long COVID individuals at baseline and follow-up.

Table 2: Follow-up group characteristics by symptom status at baseline and follow-up.

**Figure 1: Study population from recruitment to follow-up.**

 

**Figure 2: Proportion of individuals with long COVID and symptoms (A: at baseline in whole cohort and in follow-up group; B: at baseline vs at follow-up in follow-up group) or impairment (C in whole cohort and in follow-up group vs healthy controls; D at baseline vs at follow-up in follow-up group).** Significant differences (p<0.05) are indicated with a star, numbers above columns indicate the sample size (n) for each group. Note for Figure 2C: compared between healthy controls (grey) and at baseline for long COVID (blue).









**Figure 3: Association between risk factors and: (A) severe breathlessness at baseline; (B) Poor HRQoL at follow-up.** Note: A) associations predicted whole cohort symptom at baseline using baseline co-variates and B) predicted follow-up symptom using follow-up co-variates in follow-up group

#

**Table 1: Characteristics of long COVID individuals at baseline and for follow-up.** P-values represent results from a paired t-test (or non-parametric equivalent), McNemar’s test for categorical and dichotomous variables.

|  | **Whole cohort** | **Follow-up group** |
| --- | --- | --- |
| **Characteristic** | **Baseline****(n=536)** | **Baseline****(n=331)** | **Follow-up****(n=331)** | **P Value (baseline vs follow-up visits)** |
| Age (years) | 45 (11) | 46 (11) | 47 (11) | - |
| Sex (n females) | 389 (73%) | 241 (73%) | 241 (73%) | - |
| BMI (kg/m2) | 25 (23, 29) | 26 (23, 30) | 26 (23,31) | 0.269 |
| Ethnicity |  |  |  | - |
|  White | 477 (89%) | 295 (89%) | 295 (89%) |  |
|  Mixed | 21 (4%) | 12 (4%) | 3 (1%) |  |
|  South Asian | 24 (4%) | 17 (5%) | 15 (5%) |  |
|  Black | 13 (2%) | 6 (2%) | 5 (2%) |  |
|  Healthcare worker | 172 (32%) | 112 (34%) | 112 (34%) | No Change |
| At least one COVID-19 vaccination | 10 (2%) | 5 (2%) | 197 (60%) | <0.001 |
| **Comorbidities and risks** |  |  |  |  |
| Smoking |  |  |  |  |
|  Never | 349 (65%) | 218 (66%) | 222 (67%) | 0.221 |
|  Current  | 14 (3%) | 7 (2%) | 7 (2%) | >0.999 |
|  Ex-smoker | 172 (32%) | 106 (32%) | 102 (31%) | 0.343 |
| BMI |  |  |  |  |
|  ≥25 kg/m2 | 293 (55%) | 200 (60%) | 200 (61%) | >0.999 |
|  ≥30 kg/m2 | 120 (22%) | 91 (27%) | 92 (28%) | 0.789 |
| Hypertension  | 44 (8%) | 33 (10%) | 37 (11%) | 0.221 |
| Diabetes  | 10 (2%) | 7 (2%) | 9 (3%) | 0.683 |
| Heart disease | 9 (2%) | 4 (1%) | 4 (1%) | No Change |
| Asthma | 101 (19%) | 62 (19%) | 56 (17%) | 0.114 |
| Hospitalised during acute COVID-19 | 72 (13%) | 57 (17%) | 57 (17%) | - |
| Time off work (days) | 56 (14, 180) | 58 (14, 150) | 125 (35, 296) | <0.001 |
| **15 common symptoms** |  |  |  |  |
|  Number reported [median (IQR)] | 10 (8, 11) | 10 (8, 11) | 3 (0, 5) | <0.001 |
|  None reported in history | 0 (0%) | 0 (0%) | 93 (28%) | <0.001 |
|  None reported in history/ questionnaires | 0 (0%) | 0 (0%) | 60 (19%) | <0.001 |
| **Symptom groups** |  |  |  |  |
|  Systemic  | 245 (46%) | 159 (48%) | 2 (1%) | <0.001 |
|  Cardiopulmonary  | 238 (44%) | 143 (43%) | 15 (5%) | <0.001 |
|  Severe breathlessness (Dyspnoea 12 ≥10) | 187 (36%) | 120 (38%) | 93 (30%) | 0.016 |
|  Cognitive dysfunction | 268 (50%) | 160 (48%) | 127 (38%) | 0.005 |
|  Poor HRQoL | 281 (55%) | 181 (57%) | 138 (45%) | <0.001 |
|  Less common symptoms only | 66 (13%) | 37 (12%) | 108 (35%) | <0.001 |
| **Duration (days: median, [IQR])** |  |  |  |  |
|  Initial symptoms-to-assessment  | 182 (132, 222) | 170 (126, 208) | 384 (350, 431) | - |
|  COVID-19 positive-to-assessment  | 110 (53, 175) | 110 (53, 170) | 328 (265, 375) | - |
| **Organ Impairment** |  |  |  |  |
|  Liver | 151 (29%) | 119 (36%) | 106 (33%) | 0.153 |
|  Heart | 102 (19%) | 71 (22%) | 70 (21%) | >0.999 |
|  Kidney | 79 (15%) | 60 (18%) | 56 (17%) | 0.583 |
|  Pancreas | 100 (20%) | 80 (26%) | 56 (22%) | 0.201 |
|  Lungs | 12 (2%) | 7 (2%) | 5 (2%) | >0.999 |
|  Spleen | 43 (8%) | 33 (10%) | 29 (9%) | 0.453 |
|  ≥1 organ | 314 (59%) | 228 (69%) | 194 (59%) | <0.001 |
|  ≥2 organs | 122 (23%) | 97 (29%) | 88 (27%) | 0.336 |

**Table 2: Follow-up group characteristics by symptom status at follow-up**. Compared are the baseline characteristics (top part) and the follow-up characteristics (bottom part) between groups that at follow-up were ongoing symptomatic or had resolved symptoms.

| **Characteristic**  | **Ongoing Symptomatic** (Symptoms reported at baseline and follow-up)**(n=264)** | **Resolved Symptoms**(No symptoms reported at follow-up)**(n=60)** | **p-value** |
| --- | --- | --- | --- |
| **Follow-up group baseline characteristics** |
| **Demographics** |   |   |  |
| Age (years)Female sex (n)BMI (kg/m2)WhiteMixedSouth AsianBlackHealthcare worker | 46 (10)204 (77%)26 (23, 30)239 (91%)3 (1%)8 (3%)3 (1%)89 (34%) | 48 (12)34 (57%)28 (23, 31)49 (82%)0 (0%)7 (12%)2 (3%)19 (32%) | 0.340**0.002**0.5190.066>0.999**0.010**0.2320.880 |
| **Comorbidities and risks** |   |   |  |
| Never smokedCurrent smokerEx-smokerBMI>=25 kg/m2BMI>=30 kg/m2HypertensionDiabetesAsthmaPre-existing heart diseaseHospitalized during acute COVID-19Number of common symptoms reported | 173 (66%)4 (2%)87 (33%)159 (60%)72 (27%)25 (9%)3 (1%)53 (20%)3 (1%)46 (17%)10 (9, 11) | 40 (67%)2 (3%)18 (30%)38 (63%)18 (30%)6 (10%)4 (7%)9 (15%)1 (2%)10 (17%)9 (7, 10) | >0.9990.3080.7600.7700.7500.813**0.024**0.4680.561>0.999**<0.001** |
| **MRI abnormality** |   |   |  |
| **Liver**cT1 or fat highcT1 (high)cT1 (ms)Fat (high)Fat (%)Volume (high)Volume (ml) | 95 (36%)36 (14%)727 (681, 770)87 (33%)3 (2, 6)23 (9%)1,423 (1,252, 1,693) | 23 (39%)9 (15%)715 (680, 768)20 (33%)3 (1, 6)6 (10%)1,463 (1,277, 1,653) | 0.7660.8360.690>0.9990.7320.8010.650 |
| **Pancreas**srT1 or fat highsrT1 highsrT1 (ms)Fat (high)Fat (%) | 64 (26%)29 (12%)720 (686, 772)51 (20%)3 (2, 6) | 14 (24%)7 (12%)722 (684, 767)12 (20%)3 (3, 5) | 0.868>0.9990.775>0.9990.287 |
| **Kidney**Cortex T1 (high)Cortex T1 left 1.5T (ms)Cortex T1 right 1.5T (ms)Cortex T1 left 3T (ms)Cortex T1 right 3T (ms)Volume (high)Volume left (ms)Volume right (ms) | 44 (17%)1,084 (74)1,072 (70)1,427 (74)1,400 (85)21 (8%)146 (129, 165)146 (128, 166) | 14 (24%)1,094 (61)1,084 (68)1,399 (54)1,382 (70)7 (12%)158 (133, 179)150 (137, 172) | 0.1930.3230.2600.2040.5090.318**0.044**0.185 |
| **Spleen**SplenomegalyVolume (ml) | 28 (11%)180 (141, 242) | 5 (8%)194 (166, 252) | 0.8130.146 |
| **Lung**FAC (low)FAC (%) | 7 (3%)44 (36, 50) | 0 (0%)43 (35, 50) | 0.3590.844 |
| **Heart**Myocardial Injury / T1 (high)Average T1 1.5T (ms)Average T1 3T (ms)LV EF (low)LV EF (%)RV EF (low)RV EF (%)LV EDV (high)LV EDV (ml)RV EDV (high)RV EDF (ml)Global longitudinal strain (high)Global longitudinal strain (%)  | 24 (9%)980 (965, 993)1,182 (31)13 (5%)60 (5)10 (4%)59 (5)2 (1%)78 (71, 87)3 (1%)75 (66, 84)11 (4%)-14 (2) | 11 (18%)972 (949, 987)1,184 (37)4 (7%)58 (5)4 (7%)58 (6)0 (0%)82 (75, 94)0 (0%)80 (70, 93)0 (0%)-14 (2) | 0.062**0.047**0.9030.531**0.029**0.3020.108>0.999**0.008**>0.999**0.005**0.2300.474 |
| **Number of organs impaired on MRI**0≥1≥2 ≥3 | 84 (32%)180 (68%)75 (28%)26 (10%) | 17 (28%)43 (72%)20 (33%)7 (12%) | 0.6460.6460.4380.641 |
| **Follow-up characteristics** |
| Hospitalized between baseline and follow-upTime off work (days) | 13 (5%)172 (42, 300) | 1 (2%)54 (21, 120) | 0.480**<0.001** |
| **MRI abnormality** |   |   |  |
| **Liver**cT1 or fat highcT1 (high)cT1 (ms)Fat (high)Fat (%)Volume (high)Volume (ml) | 88 (35%)40 (16%)724 (693, 768)74 (29%)3 (2, 6)24 (9%)1,427 (1,271, 1,699) | 17 (28%)7 (12%)708 (676, 755)16 (27%)3 (2, 6)5 (8%)1,474 (1,316, 1,675) | 0.4470.5470.1500.7540.877>0.9990.429 |
| **Pancreas**srT1 or fat highcT1 highsrT1 (ms)Fat (high)Fat (%) | 43 (22%)16 (8%)720 (684, 754)35 (18%)3 (2, 5) | 10 (21%)4 (8%)700 (673, 740)10 (20%)3 (2, 6) | >0.999>0.9990.1130.6830.989 |
| **Kidney**Cortex T1 (high)Cortex T1 left 1.5T (ms)Cortex T1 right 1.5T (ms)Cortex T1 left 3T (ms)Cortex T1 right 3T (ms)Volume (high)Volume left (ms)Volume right (ms) | 45 (17%)1,086 (58)1,082 (53)1,422 (91)1,404 (85)21 (8%)145 (127, 165)149 (129, 167) | 9 (15%)1,086 (67)1,078 (67)1,424 (53)1,393 (59)6 (10%)158 (137, 180)156 (143, 172) | 0.8480.9490.7020.9310.6050.610**0.011****0.028** |
| **Spleen**SplenomegalyVolume (ml) | 24 (9%)176 (139, 246) | 5 (8%)192 (161, 245) | >0.9990.074 |
| **Lung**FAC (low)FAC (%) | 4 (2%)45 (38, 52) | 0 (0%)45 (38, 52) | 0.5800.752 |
| **Heart**Myocardial Injury / T1 (high)Average T1 1.5T (ms)Average T1 3T (ms)LV EF (low)LV EF (%)RV EF (low)RV EF (%)LV EDV (high)LV EDF (ml)RV EDV (high)RV EDF (ml)Global longitudinal strain (high)Global longitudinal strain (%)  | 25 (9%)982 (969, 992)1,182 (38)6 (2%)60 (4)7 (3%)59 (5)2 (1%)78 (70, 86)4 (2%)74 (66, 86)15 (6%)-15 (2) | 7 (12%)975 (960, 987)1,184 (48)2 (3%)58 (5)5 (8%)57 (5)0 (0%)82 (75, 92)0 (0%)81 (72, 91)5 (8%)-14 (2) | 0.6320.0690.8950.644**0.013**0.051**0.014**>0.999**0.012**>0.999**0.015**0.551**0.017** |
| **Number of organs impaired on MRI**0≥1≥2 ≥3 | 112 (42%)152 (58%)73 (28%)28 (11%) | 23 (38%)37 (62%)13 (22%)5 (8%) | 0.6640.6640.4190.813 |